Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Etelcalcetide (Parsabiv) vs Pasireotide (Signifor)
An educational, source-based comparison of Etelcalcetide (Parsabiv) and Pasireotide (Signifor) — how each peptide works, what it's researched for, and what to know before going deeper.
Calcimimetic peptide for secondary hyperparathyroidism on hemodialysis.
Synthetic D-amino-acid peptide that binds the calcium-sensing receptor on parathyroid chief cells, increasing its sensitivity to extracellular calcium and lowering PTH secretion.
- Secondary hyperparathyroidism in adults on chronic hemodialysis
- • FDA-approved.
- • Hypocalcemia common; monitor calcium and avoid in low corrected calcium.
Multi-receptor somatostatin analog for Cushing's disease and acromegaly.
Cyclohexapeptide somatostatin analog binding somatostatin receptors SST1, 2, 3, and 5 (with highest affinity for SST5), suppressing ACTH in corticotroph adenomas and GH/IGF-1 in somatotroph tumors.
- Cushing's disease
- Acromegaly (LAR formulation)
- • FDA-approved.
- • Significant hyperglycemia risk requires glucose monitoring.
- • Bradycardia and QT prolongation possible.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Etelcalcetide (Parsabiv) | Etelcalcetide vs cinacalcet | JAMA | 2017 | Non-inferior PTH reduction with IV administration. |
| Pasireotide (Signifor) | Pasireotide in Cushing's disease (Phase III) | NEJM | 2012 | Reduced urinary free cortisol with dose-dependent hyperglycemia. |
Side-effect & safety grid
- FDA-approved.
- Hypocalcemia common; monitor calcium and avoid in low corrected calcium.
- FDA-approved.
- Significant hyperglycemia risk requires glucose monitoring.
- Bradycardia and QT prolongation possible.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Etelcalcetide (Parsabiv) vs Pasireotide (Signifor) — Key differences
- Class: Etelcalcetide (Parsabiv) is classified as Calcium-Sensing Receptor Agonist · Endocrine, while Pasireotide (Signifor) is Somatostatin Analog · Endocrine.
- Primary research focus: Etelcalcetide (Parsabiv) — secondary hyperparathyroidism in adults on chronic hemodialysis; Pasireotide (Signifor) — cushing's disease.
- Tag: FDA-Approved · Endocrine vs FDA-Approved · Endocrine.